TABLE 1.
Study characteristics | Convalescent plasma | Control | Comparison | ||||||
---|---|---|---|---|---|---|---|---|---|
Variable | No. Studies | Events (n/N) | Prop (95% CI) | Events (n/N) | Prop (95% CI) | OR (95% CI) | P‐value | I 2 (95% CI) | P‐value (Q) |
Male Sex | 13 | 1484/2196 | 0.647 (0.562; 0.723) | 1760/2615 | 0.679 (0.591; 0.755) | 0.97 (0.85; 1.10) | .633 | 0.0% (0.0; 58.9%) | .392 |
IVIG Use | 3 | 19/287 | 0.241 (0.150; 0.364) | 25/293 | 0.298 (0.183; 0.445) | 1.30 (0.56; 3.03) | .539 | 0.0% (0.0; 79.0%) | .609 |
Steroid Use | 10 | 806/1164 | 0.659 (0.629; 0.688) | 1027/1632 | 0.609 (0.582; 0.635) | 1.04 (0.87; 1.23) | .849 | 59.0 (14.4; 80.4%) | .012 |
Oxygen Use | 10 | 750/929 | 0.891 (0.861; 0.914) | 1048/1271 | 0.825 (0.795; 0.851) | 1.73 (1.24; 2.42) | .001 | 80.8% (55.1; 91.8%) | <.001 |
Antiviral Use | 10 | 1376/1682 | 0.675 (0.618; 0.728) | 1510/1761 | 0.691 (0.645; 0.733) | 0.83 (0.58; 1.17) | .278 | 0.0% (0.0; 16.6%) | .911 |
Diabetes | 13 | 752/2207 | 0.349 (0.329; 0.370) | 904/2633 | 0.348 (0.330; 0.367) | 1.04 (0.92; 1.18) | .538 | 0.0% (0.0; 41.1%) | .716 |
HTN | 12 | 1028/2168 | 0.480 (0.459; 0.501) | 1203/2477 | 0.489 (0.469; 0.509) | 0.95 (0.84; 1.07) | .422 | 0.0% (0.0; 57.3%) | .465 |
COPD | 7 | 93/990 | 0.107 (0.088; 0.129) | 136/1344 | 0.120 (0.102; 0.140) | 1.02 (0.76; 1.37) | .901 | 17.1% (0.0; 61.0%) | .300 |
CKD | 9 | 130/1897 | 0.076 (0.064; 0.089) | 202/2142 | 0.101 (0.088; 0.115) | 0.81 (0.64; 1.02) | .072 | 14.9% (0.0; 57.0%) | .309 |
CVD | 9 | 349/1878 | 0.223 (0.203; 0.245) | 438/2130 | 0.238 (0.219; 0.259) | 0.90 (0.76; 1.06) | .200 | 0.0% (0.0; 18.3%) | .903 |
Cerebrovascular disease | 3 | 17/351 | 0.058 (0.003; 0.544) | 20/467 | 0.029 (0.001; 0.499) | 1.30 (0.63; 2.68) | .477 | 0.0% (0.0; 87.9%) | .425 |
Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; HTN, hypertension; OR, odds ratio.